TY - JOUR
T1 - Ellagic acid and hydroxyapatite promote angiogenesis marker in bone defect
AU - Nirwana, Intan
AU - Munadziroh, Elly
AU - Yuliati, Anita
AU - Fadhila, Azalia Izzah
AU - Nurliana,
AU - Wardhana, Agung Satria
AU - Shariff, Khairul Anuar
AU - Surboyo, Meircurius Dwi Condro
N1 - Funding Information:
This study was funded by the Faculty of Dental Medicine at Universitas Airlangga 2021 in the schema Penelitian Unggulan Fakultas (PUF) with grant number 219/UN3.1.2/PT/2021 .
Publisher Copyright:
© 2021 Craniofacial Research Foundation
PY - 2022/1/1
Y1 - 2022/1/1
N2 - The combination of hydroxyapatite and the herbal extract ellagic acid is expected to accelerate the bone healing process (osteogenesis) due to the extract's anti-inflammatory and antioxidant properties. The osteogenesis process is closely associated with angiogenesis markers, such as fibroblast growth factor 2 (FGF-2), vascular endothelial growth factor (VEGF) and alkali phosphatase (ALP). The objective of this study is to analyse the combination of ellagic acid and hydroxyapatite to promote FGF-2, VEGF and ALP expression as angiogenesis markers in a bone defect model. The research sample comprised 30 male Wistar rats with a defect introduced on the left femur; these were divided into three groups for treatment with ellagic acid and hydroxyapatite, hydroxyapatite and polyethylene glycol (PEG) (control). On days 7 and 14 days after treatment, the Wistar rats were euthanised, and the femoral bone tissue was removed for the immunohistochemical analysis of FGF-2, VEGF and ALP expression. FGF-2 and ALP expression increased in the group treated with ellagic acid and hydroxyapatite on days 7 and 14 post treatment (p < 0.05), and there was an increase in VEGF expression on day 7 post treatment (p < 0.05). The combination of ellagic acid and hydroxyapatite promoted FGF-2, VEGF and ALP expression as angiogenesis markers in the bone defect model.
AB - The combination of hydroxyapatite and the herbal extract ellagic acid is expected to accelerate the bone healing process (osteogenesis) due to the extract's anti-inflammatory and antioxidant properties. The osteogenesis process is closely associated with angiogenesis markers, such as fibroblast growth factor 2 (FGF-2), vascular endothelial growth factor (VEGF) and alkali phosphatase (ALP). The objective of this study is to analyse the combination of ellagic acid and hydroxyapatite to promote FGF-2, VEGF and ALP expression as angiogenesis markers in a bone defect model. The research sample comprised 30 male Wistar rats with a defect introduced on the left femur; these were divided into three groups for treatment with ellagic acid and hydroxyapatite, hydroxyapatite and polyethylene glycol (PEG) (control). On days 7 and 14 days after treatment, the Wistar rats were euthanised, and the femoral bone tissue was removed for the immunohistochemical analysis of FGF-2, VEGF and ALP expression. FGF-2 and ALP expression increased in the group treated with ellagic acid and hydroxyapatite on days 7 and 14 post treatment (p < 0.05), and there was an increase in VEGF expression on day 7 post treatment (p < 0.05). The combination of ellagic acid and hydroxyapatite promoted FGF-2, VEGF and ALP expression as angiogenesis markers in the bone defect model.
KW - Angiogenesis
KW - Ellagic acid
KW - Human & health
KW - Hydroxyapatite
UR - http://www.scopus.com/inward/record.url?scp=85119046403&partnerID=8YFLogxK
U2 - 10.1016/j.jobcr.2021.11.008
DO - 10.1016/j.jobcr.2021.11.008
M3 - Article
AN - SCOPUS:85119046403
SN - 2212-4268
VL - 12
SP - 116
EP - 120
JO - Journal of Oral Biology and Craniofacial Research
JF - Journal of Oral Biology and Craniofacial Research
IS - 1
ER -
